Patents by Inventor Rafael Maldonado Lopez

Rafael Maldonado Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS
    Publication number: 20240059737
    Abstract: The present invention relates to compounds of formula (I) AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D- Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 (I) or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.
    Type: Application
    Filed: October 2, 2020
    Publication date: February 22, 2024
    Inventors: Vicent CASADÓ BURILLO, Estefania MORENO GUILLEN, Rafael MALDONADO LÓPEZ, David ANDREU MARTINEZ, Maria GALLO, Leonardo PARDO CARRASCO, Miguel CASTANHO, Vera NEVES, Marco CAVACO
  • Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
    Patent number: 9662320
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: May 30, 2017
    Assignee: Universitat Pompeu Fabra
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez
  • Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities
    Publication number: 20160067235
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Application
    Filed: March 19, 2013
    Publication date: March 10, 2016
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez